Physician profile
Lan Wang
NPI 1720432420
$3,930.89
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $922 · 2021: $1,190 · 2022: $600.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $519.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $506.72 | 2019-2021 | |
| Celgene Corporation | $493.12 | 2020-2022 | |
| Genzyme Corporation | $359.62 | 2020-2022 | |
| Amgen INC. | $347.18 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $328.65 | 2019-2021 | |
| Seagen INC. | $272.09 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $190.53 | 2019-2022 | |
| Exelixis INC. | $160.32 | 2019 | |
| Incyte Corporation | $128.40 | 2019-2022 | |
| Epizyme, INC. | $125.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.04 | 2019 | |
| Akcea Therapeutics, INC. | $118.80 | 2019 | |
| Agios Pharmaceuticals, INC. | $113.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $87.51 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $40.64 | 2022 | |
| Pfizer INC. | $16.54 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.